Therapy of chronic myeloid leukemia: twilight of the imatinib era?
about
Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells.Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell TransplantationTargeted therapy: resistance and re-sensitization.The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
P2860
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
@en
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
@nl
type
label
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
@en
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
@nl
prefLabel
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
@en
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
@nl
P2860
P356
P1433
P1476
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
@en
P2093
Janusz Błasiak
Sylwester Glowacki
P2860
P304
P356
10.1155/2014/596483
P577
2014-01-30T00:00:00Z